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Ataxia, causing imbalance, dizziness and falls, is a leading cause of neurological disability. We have recently identified a biallelic
intronic AAGGG repeat expansion in replication factor complex subunit 1 (RFC1) as the cause of cerebellar ataxia, neuropathy,
vestibular areflexia syndrome (CANVAS) and a major cause of late onset ataxia. Here we describe the full spectrum of the disease
phenotype in our first 100 genetically confirmed carriers of biallelic repeat expansions in RFC1 and identify the sensory neuropathy
as a common feature in all cases to date. All patients were Caucasian and half were sporadic. Patients typically reported progres-
sive unsteadiness starting in the sixth decade. A dry spasmodic cough was also frequently associated and often preceded by decades
the onset of walking difficulty. Sensory symptoms, oscillopsia, dysautonomia and dysarthria were also variably associated. The
disease seems to follow a pattern of spatial progression from the early involvement of sensory neurons, to the later appearance of
vestibular and cerebellar dysfunction. Half of the patients needed walking aids after 10 years of disease duration and a quarter
were wheelchair dependent after 15 years. Overall, two-thirds of cases had full CANVAS. Sensory neuropathy was the only
manifestation in 15 patients. Sixteen patients additionally showed cerebellar involvement, and six showed vestibular involvement.
The disease is very likely to be underdiagnosed. Repeat expansion in RFC1 should be considered in all cases of sensory ataxic
neuropathy, particularly, but not only, if cerebellar dysfunction, vestibular involvement and cough coexist.
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Introduction
Imbalance, together with dizziness and falls, is one of the
leading causes of neurological disability with an estimated
prevalence of up to 30% in adults over 65 years of age (Lin
and Bhattacharyya, 2012; Hartholt et al., 2019). A key
feature of normal balance function is the cross-modal inte-
gration of visual, proprioceptive, and vestibular afferents
that also undergo cerebellar modulation. Failure across
any of these systems can lead to imbalance with resulting
ataxia, but the cause remains elusive in a significant pro-
portion of cases.
We have recently identified a biallelic intronic repeat ex-
pansion in replication factor complex subunit 1 (RFC1) as
a major cause of late onset ataxia (Cortese et al., 2019).
The cerebellum, the sensory neurons and the vestibular
system can all be affected in this neurodegenerative dis-
order, which has also been termed cerebellar ataxia, neur-
opathy, vestibular areflexia syndrome (CANVAS)
(Szmulewicz et al., 2011).
Since the original descriptions of this syndrome
(Bronstein et al., 1991), there have been a growing
number of studies describing the clinical features of
CANVAS (Migliaccio et al., 2004; Szmulewicz et al.,
2011; Wu et al., 2014; Cazzato et al., 2016; Infante
et al., 2018; Pelosi et al., 2018; Taki et al., 2018).
Although these descriptions are useful, these reports were
limited by the inclusion of patients using purely clinical
criteria (Szmulewicz et al., 2016). Therefore, the detailed
phenotypic spectrum of RFC1 repeat expansion has yet
to be fully elucidated.
Here we report our first 100 genetically confirmed pa-
tients carrying a biallelic AAGGG repeat expansion in
RFC1. Clinical presentation, phenotypic heterogeneity and
progression of the disease are discussed.
Materials and methods
Patients
DNA samples (n = 363) were collected from patients diag-
nosed with adult-onset ataxia or CANVAS at the National
Hospital for Neurology and Neurosurgery at Queen Square
(London, UK) and in neurological centres in New Zealand,
France, Italy, Brazil, Slovenia Australia and the UK. Clinical
data were gathered using a standardized proforma. After
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reviewing the clinical charts, the following information was
collected for all cases tested: demographics, family history,
diagnosis, clinical and/or investigational evidence of sensory
neuropathy, cerebellar dysfunction/atrophy, vestibular are-
flexia and the presence/absence of additional atypical features
for CANVAS (e.g. associated parkinsonism, spasticity, cogni-
tive decline). Additional information was collected in cases
testing positive for biallelic RFC1 expansions: history of
cancer, prior alternative diagnoses, symptoms and age of
symptom onset, use of walking aids, first neurological exam-
ination available, autonomic testing, previous genetic testing
and muscle or nerve biopsy.
Clinical involvement of the main systems affected in RFC1
repeat expansion associated CANVAS were defined as follows:
(i) sensory neuropathy/neuronopathy: sensory symptoms (loss
of feeling, paraesthesia, dysesthesia, neuropathic pain) and/or
abnormal sensory examination including sensory ataxia; (ii) bi-
lateral vestibulopathy: presence of head movement-induced
oscillopsia and/or abnormal head impulse test; and (iii) cere-
bellar dysfunction: cerebellar dysarthria and/or dysphagia, ab-
normal eye movements (nystagmus, dysmetric saccades,
broken pursuit). Investigational involvement was further
defined by (i) sensory neuropathy/neuronopathy on nerve con-
duction studies; (ii) bilaterally abnormal video head impulse
test, bithermal caloric or motorized rotational tests; and (iii)
cerebellar atrophy on brain MRI. We defined full CANVAS
cases as those with a combined involvement of the sensory
peripheral nerves, vestibular system and the cerebellum in the
absence of atypical features.
The study was approved by local institutional ethical com-
mittees. Written informed consent was obtained from patients,
all aged over 18 years, participating in the study.
RFC1 pentanucleotide repeat
expansion testing
Flanking polymerase chain reaction (PCR) and repeat-primed
PCRs for the pathogenic AAGGG and non-pathogenic
AAAGG or AAAAG repeat expansions in RFC1 were per-
formed as previously described (Cortese et al., 2019).
Positive cases were defined as samples showing no PCR ampli-
fiable product on flanking PCR, negative repeat primed PCR
for (AAAGG)exp and (AAAAG)exp configurations, and the
presence of a decremental saw-tooth pattern on repeat
primed PCR for the pathogenic AAGGG repeat expansion. If
a sufficient amount of DNA was available, Southern blotting
was performed according to our previously-described protocol
in positive cases to confirm the presence and measure the size
of the AAGGG repeat expansions (Cortese et al., 2019).
MRI
Brain and spine scans were performed according to standard
clinical protocols. Axial fluid-attenuated inversion recovery
(FLAIR), coronal T2-weighted and 3D T1 sequences were
used to evaluate cerebellar atrophy and sagittal and axial T2-
weighted images were performed to evaluate spinal cord
atrophy.
Nerve conduction studies
Surface orthodromic motor (median, ulnar, posterior tibial,
peroneal nerves) and antidromic (orthodromic for ulnar and
median in UK centres) sensory (median, ulnar, radial, sural
and/or superficial peroneal nerves) nerve conduction studies
were performed according to standard procedures (Preston
and Shapiro, 2013). Amplitudes of distal compound muscular
action potential and sensory action potential were measured
from baseline to negative peak. Potentials in the upper and
lower limbs were considered absent when all potentials of
nerves tested were not recordable and reduced when at least
one potential had reduced amplitude according to the normal
value of each centre.
Vestibular testing
Bilaterally reduced or absent angular vestibulo-ocular reflex
function was documented by at least one of the following
tests (Strupp et al., 2017).
Bilaterally abnormal video head impulse test
The horizontal angular vestibulo-ocular reflex velocity gain
(the ratio of eye velocity to head velocity) was quantified by
a video-oculography system and an accelerometer that mea-
sured eye and head velocity during passive, unpredictable, im-
pulsive (10–10 amplitude, 150–300/s acceleration) head
turns delivered by the examiner in the plane of the horizontal
canal in both directions (left and right), while subjects were
required to stare at a head fixed target at eye level (Bronstein
et al., 2015).
Bilaterally reduced caloric response
The low frequency angular vestibulo-ocular reflex was tested
using a video-oculography system and an irrigation unit. The
horizontal canal of each ear was irrigated with cold (30C)
and warm (44C) water. Eye movements were recorded after
each irrigation and the maximal slow-phase velocity of caloric
induced nystagmus was measured (Cousins et al., 2013).
Reduced vestibulo-ocular reflex gain tested using a
rotatory chair
Peak slow-phase eye velocity was recorded by a video-oculo-
graphy system while the subjects were rotated on a motorized
chair. The chair was rapidly accelerated (1 s) in the yaw plane
to a constant velocity of 90/s using a rotational step stimulus
(Okada et al., 1999). Vestibulo-ocular reflex gain (the ratio of
eye velocity to chair velocity during sinusoidal chair rotation
in the range from 0.05 to 0.1 Hz) and time constant (the rate
of decay of slow phase eye velocity during constant velocity
steps rotation) were recorded.
Autonomic assessment
Parasympathetic function was assessed by ECG monitoring of
heart rate variation during Valsalva manoeuvre, deep breath-
ing and standing (Ewing et al., 1985). Sympathetic function
was assessed by measuring blood pressure response to change
in posture and handgrip and sympathetic skin response.
Parasympathetic or sympathetic function were considered im-
paired if at least one test was definitely abnormal.
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Neuropathological examination
Nerve biopsies were processed according to local standard
operating procedures. In brief, fresh biopsies, immediately
after removal, were divided in half, with one portion fixed in
10% buffered formalin, followed by tissue processing and
embedding in paraffin and the other portion fixed in 3% glu-
taraldehyde, followed by processing into epoxy resin. The par-
affin embedded tissues were cut at 5-mm thin sections and
stained with a battery of histochemical and immunohistochem-
ical stains (including immunostaining for neurofilaments with
SMI31 antibody (1:5000; Sternberger, shown in Fig. 3) and
the resin-embedded tissues were cut into 1-mm semi-thin sec-
tions and stained with methylene blue azure-basic fuchsin. All
slides were viewed under light microscope. Histology images
shown in the Fig. 3 were digitized on a LEICA SCN400F
scanner at 40 magnification and 65% image compression
setting during export. For the preparation of light microscopy
images, image captures were taken in LEICA SlidePath (LEICA
Milton Keynes, UK). Publication figures were assembled in
Adobe Photoshop.
For the analysis of myelinated fibre density in sural nerve
biopsies, four randomly selected fascicles from each case were
assessed. Both large and small myelinated fibres were counted.
Statistical analyses
Continuous data are expressed as median (minimum–max-
imum). Spearman’s correlation coefficient was calculated to
test the association of repeat expansion size and age of neuro-
logical onset, age at onset of unsteadiness, time-to-use of a
stick and disease severity, as indicated by the number of sys-
tems involved (cerebellar, peripheral nerve, vestibular system).
Mann-Whitney test was used to compare the repeat expansion
size in patients with and without history of cancer. All ana-
lyses were performed using STATA statistical software, version
14.
Data availability
Anonymized data from this study will be shared by request
from any qualified investigator.
Results
Genetic screening for RFC1 AAGGG
expansion
From the 363 recruited cases, we identified 105 patients
carrying the biallelic AAGGG repeat expansion in RFC1.
We have reported limited clinical details of 56 cases in our
original paper describing the RFC1 repeat expansion
(Cortese et al., 2019) and add here 49 further cases identi-
fied by screening additional DNA samples.
Overall, the biallelic AAGGG repeat expansion in RFC1
was identified in 63/70 (90%) of DNA samples from pa-
tients with full CANVAS and 42/293 (14%) of DNA sam-
ples from a range of other adult onset ataxia cases.
In 51 cases for which sufficient DNA was available,
Southern blotting was performed confirming the presence
of repeat expansions of both alleles in all cases. Expansion
size ranged from 433 to 2750 repeat units, with a median
size of 989 repeats for the smaller allele and 1802 for the
larger allele. In 24 cases the expanded alleles had similar
size as shown by the presence of one discrete band on
Southern blot.
Patient demographics and previous
diagnoses
Detailed clinical information was available from 100 of
105 genetically confirmed cases, which are considered
here for further analysis.
There were 45 male and 55 female patients. Forty-five
cases from 26 families had a positive family history with
at least one sibling affected or an affected cousin (three
families), while in 55 cases the disease was sporadic.
Median age at the time of this study was 72 years (range
45–95). All patients were Caucasian.
Fifty-one cases were routinely seen in peripheral nerve/
neuromuscular clinics, 16 in general neurology clinics, 20
in neurogenetic clinics, seven in ataxia clinics and six in
neuro-otology clinics.
CANVAS was the initial diagnosis in only 23 cases.
Twenty-two cases were considered to have a pure sensory
neuropathy or neuronopathy; 23 further patients were
defined as having a complex neurological disorder but
not actual CANVAS, including complex neuropathy
(n = 14), complex ataxia (n = 7) or complex vestibular syn-
dromes (n = 2), depending on the predominant system
involved. Thirty-two patients received an alternative likely
diagnosis in the first instance including spino-cerebellar
ataxia (n = 16), mitochondrial disease (n = 6), multisystem
atrophy-cerebellar subtype (n = 3), cerebrovascular disease
(n = 2), hereditary sensory neuropathy (n = 2), hereditary
spastic paraplegia (n = 1), paraneoplastic disease (n = 1)
and Sjo¨gren’s syndrome (n = 1).
Past medical history
As the repeat-hosting gene RFC1 encodes for the largest
subunit of the replication factor complex, essential to
DNA replication and repair, detailed data concerning
cancer history were also collected. Twelve patients reported
a positive history of cancer as follows: breast (n = 5), pros-
tate (n = 1), gastric (n = 1), lymphoma (n = 1), parathyroid
(n = 1), metastatic disease with unknown primary (n = 1),
basal cell carcinoma (n = 1), melanoma and bowel adeno-
carcinoma in the same patient. This was similar to the 14%
of positive neoplasm history observed in 100 randomly
chosen ataxia patients from the National Hospital for
Neurology and Neurosurgery, Queen Square (London,
UK), with the same age and gender distribution as RFC1
positive cases and who tested negative for RFC1 repeat
expansion (P = 0.69).
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Symptoms at onset and during
disease progression
Median age of any neurological onset of the disease (cough
excluded) was 52 years, ranging from 19 to 76 years.
Frequency of symptoms and age distribution of their
onset are summarized in Fig. 1A and B. Detailed clinical
information for each case is provided in Supplementary
Table 1.
Progressive imbalance was reported by 96 patients, at a
median age of 55 years (range 30–80), and was considered
the presenting symptom in 50 patients.
Seventy-six patients complained of sensory symptoms,
including loss of feeling (n = 52), pins and needles
(n = 27), neuropathic pain (n = 42). In 18 cases sensory
symptoms were reported at disease onset.
Oscillopsia, defined as a visual disturbance in which ob-
jects appear to oscillate during head movements, is a
common sequela of a bilaterally impaired vestibulo-ocular
reflex, and was reported by 32 patients and in six at disease
onset.
Dysarthria and dysphagia, secondary to cerebellar dys-
function, were reported in 52 and 27 patients, respectively,
but were rarely the presenting symptom. Rather, they
tended to appear later in the disease course.
Symptoms of autonomic dysfunction, including postural
hypotension (n = 13), erectile dysfunction (n = 7), chronic
constipation (n = 7), urinary dysfunction (n = 8) and anhi-
drosis (n = 3) were reported by 32 patients, but these were
usually mild and tended to appear late.
Notably, 64 patients complained of chronic cough, which
could precede the onset of neurological symptoms by three
decades and was the initial symptom in a third of all cases.
The disease had a slowly progressive course. Fifty-five
patients needed a stick after 10 years of disease duration
(range 0–42) and 25 were wheelchair-dependent after 15
years of disease duration (range 2–38). At the time of this
study 12 patients had died. Median age of death was 77
years (range 59–87).
We did not observe a significant correlation between the
size of the smaller allele, larger allele or their sum and age
of neurological onset (cough excluded), age at onset of
unsteadiness, time-to-use of a stick or disease severity as
indicated by number of systems involved (Supplementary
Fig. 1). Also, there was no difference in repeat expansion
size between patients with and without history of cancer.
Neurological examination
Neurological examination was performed after 10 (0–50)
years from recorded neurological disease onset (Table 1).
Seventy-nine cases had ataxic gait and 83 had a positive
Romberg’s sign. Eye movement examination was abnormal
in 65 cases, showing nystagmus (n = 55), broken pursuit
(n = 42) or dysmetric saccades (n = 41), suggesting the pres-
ence of an underlying cerebellar dysfunction. Dysarthric
speech, although understandable, was noted in 40 patients.
Bedside head impulse test was performed in 32 cases and
showed bilateral vestibular hypofunction (catch-up sac-
cades) in 28 of them (87%) (Supplementary Video 1).
Pinprick sensation was reduced in the face in 22, in the
upper limbs in 55, in the lower limbs in 74 patients.
Vibratory sensation was abnormal in the upper limbs in
41 and in the lower limbs in 84 cases. Joint position was
generally preserved in the upper limbs but abnormal in less
than half of the patients in the lower limbs. Muscle bulk
and strength were preserved, while tone was reduced in
seven cases. Deep tendon reflexes in the upper limbs and
patellar reflex in the lower limbs were normally elicitable in
half, reduced or absent in a quarter and brisk in another
quarter of cases. Ankle reflexes were more frequently
reduced or absent but retained or even brisk ankle jerks
were observed in 45 cases. Plantar responses were flexor in
all patients.
Investigations
Results of investigations performed are summarized in
Table 2. Nerve conduction study data were available in
95 patients. Sensory conduction was invariably abnormal,
with sensory action potentials either reduced or absent in
the upper limbs and usually absent in the lower limbs.
Conduction velocities were either normal or reduced
within the range expected based on sensory fibre loss.
Motor conduction was normal or mildly reduced consistent
with axonal loss. Compound muscle action potentials were
considered reduced for age in the lower limbs in 10 cases
and in the upper limbs in two cases.
Spine MRI was performed in 42 cases and showed cord
atrophy and T2 hyperintensity in the posterior column in
45% (n = 19) and 12% (n = 4), respectively.
Cerebellar atrophy, mainly involving the vermis, was
observed in 63% (n = 57) of 91 cases who underwent
brain MRI. A third of cases also had supratentorial white
matter changes, of putative microvascular origin.
Vestibular testing was performed in 53 cases and showed
the presence of bilateral vestibular hypofunction in 91% of
them (n = 48), including three cases with normal bedside
head impulse test.
Autonomic testing was performed in 42 cases and was
abnormal in half, showing either a primary sympathetic
(n = 11/32, 34%), parasympathetic (n = 9/36, 25%) or
mixed sympathetic and parasympathetic (n = 10/42, 24%)
dysfunction.
Patients underwent multiple additional investigations to
rule out other acquired or hereditary disorders. In particu-
lar, a muscle biopsy was performed in 16 cases in which a
mitochondrial disease was suspected and was either normal
or showed mild non-specific changes. Fifteen cases under-
went a nerve biopsy to rule out an inflammatory or vascu-
litic cause of the neuropathy. Nerve biopsies typically
showed a severe chronic loss of large and small myelinated
fibres without any active axonal degeneration and no re-
generation (Fig. 3). In eight cases sural nerve biopsy was
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Figure 1 Disease onset and progression. (A) Symptoms at disease onset and during disease progression in 100 biallelic RFC1 expansion
carriers. Patients reporting a combination of symptoms (unsteadiness, cough, sensory symptoms, oscillopsia, dysautonomia, dysarthria, dysphagia)
are also represented in the last two columns (multiple symptoms). (B) Age distribution of symptoms and disease milestones. The ends of the
boxes represent the upper and lower quartiles, the median is marked by a vertical line within the box. The whiskers extend to the highest and
lowest observations with outliers represented as circles outside the whiskers.
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reviewed to quantify fibre loss. Myelinated fibre nerve dens-
ity was severely reduced (median 290 myelinated fibres per
mm2 cross-sectional area, ranging from 52 to 2067) com-
pared to age-matched controls [normal range 4000–9000
myelinated fibres/mm2 (Ochoa and Mair, 1969; Jacobs and
Love, 1985)]. There was no significant variation of fibre
density across the fascicles (median 28 myelinated fibres
per fascicle, ranging from 4 to 81). The fibre loss was
not accompanied by any significant regeneration and
there was no active axonal degeneration. There was also
no evidence of demyelination.
Extensive genetic testing was performed and was negative
including Friedreich’s ataxia repeat expansion (n = 56),
common SCAs repeat expansions (n = 54), mitochondrial
DNA sequencing (n = 37), DNA polymerase gamma
(POLG) sequencing (n = 5) and next-generation sequencing
targeted panels encompassing genes associated with neur-
opathy and/or ataxia (n = 25).
Multisystem involvement of RFC1
repeat expansion
Based on symptoms and neurological examination, 94 pa-
tients had clinical evidence of sensory neuropathy/neurono-
pathy, 73 of cerebellar dysfunction and 55 of vestibular
impairment (Fig. 2A). After investigations, two-thirds of
the patients showed involvement of the three main systems
implicated in CANVAS. A subclinical sensory neuropathy
was identified in six cases confirming a sensory neuropathy
in 100% of cases, cerebellar atrophy in six patients without
clinical evidence of cerebellar dysfunction and subclinical
vestibular impairment in an additional 14 patients. In 15
cases an isolated sensory neuropathy remained the only
manifestation of the disease (Fig. 2B). However, video
Table 1 Patients demographics and neurological
examination
n = 100
Demographics
Male 45
Positive family history 45
Age of onset 52 (range 19–76)
Age at examination 63 (range 33–82)
History of cancer 12
Previous misdiagnosis 32
Neurological examination 79
Ataxic gait
Positive Romberg 83
Dysarthria 40
Abnormal eye movements 65
Nystagmus 55
Broken pursuit 42
Dysmetric saccades 41
Abnormal head impulse test 28/32 (87%)
Sensation
Abnormal pinprick face 22
Abnormal pinprick upper limbsa 55
Abnormal pinprick lower limbsb 74
Abnormal vibration upper limbs 41
Abnormal vibration lower limbs 84
Abnormal joint position upper limbs 10
Abnormal joint position lower limbs 48
Muscle strength
Distal weakness upper limbs 0
Distal weakness lower limbs 0
Reflexes
Upper limb reflexes
Normal 54
Brisk 26
Reduced 12
Absent 8
Knee reflexes
Normal 47
Brisk 28
Reduced 13
Absent 12
Ankle reflexes
Normal 30
Brisk 15
Reduced 6
Absent 49
Coordination
Abnormal finger-nose 49
Abnormal heel-shin 52
aAbsent = 12/55 (22%), patchy = 2/55 (4%), length dependent pattern n = 41/55 (74%).
bAbsent = 13/74 (18%), patchy = 4/74 (5%), length dependent pattern n = 57/74 (77%).
Table 2 Investigations
Investigation n/available
data (%)
Abnormal sensory nerve conduction study 95/95 (100)
Sensory action potential upper limbs
Reduced 40/92 (45)
Absent 52/92 (57)
Sensory action potential lower limbs
Reduced 15/90 (17)
Absent 75/90 (83)
Reduced amplitude of compound motor action
potential in upper limbs
2/94 (2)
Reduced amplitude of compound motor action
potential in lower limbs
10/93 (11)
Spinal cord atrophy on cervical MRI 19/42 (45)
Posterior column changes on cervical MRI 4/34 (12)
Cerebellar atrophy on brain MRIa 57/91 (63)
Cerebral atrophy on brain MRIa 17/91(19)
White matter changes on brain MRI 31/91 (34)
Bilateral vestibular impairment 48/53 (91)
Autonomic dysfunction
Parasympathetic dysfunctionb 9/36 (25)
Sympathetic dysfunctionc 11/32 (34.4)
Combined parasympathetic and sympathetic
dysfunction
10/42 (23.8)
aOne patient only had brain CT scan.
bHeart rate during Valsalva manoeuvre, deep breath and standing.
cBlood pressure during change in posture and handgrip; sympathetic sudomotor
response.
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head impulse test was performed (normal) in only two of
them. Therefore, subclinical vestibular involvement cannot
be excluded in patients with isolated sensory neuropathy.
Discussion
This paper explores the phenotypic spectrum of biallelic
AAGGG repeat expansions in RFC1 in our first 100 gen-
etically confirmed patients.
The cases were enrolled from multiple centres across
three continents, however, despite the ethnically heteroge-
neous populations living in these countries, all genetically
confirmed patients are Caucasian, and only 50% reported
a positive family history for the disease.
Two-thirds of genetically confirmed cases had full
CANVAS after clinical examination and investigations; a
complex sensory ataxia with cerebellar or vestibular in-
volvement was identified in 16 and six, respectively, while
in 15 a sensory neuropathy was the only clinically detect-
able manifestation of the disease. None had isolated cere-
bellar syndrome or pure bilateral vestibular failure. The
disease is slowly progressive, but often disabling with half
of the patients needing a stick after 10 years of disease
duration and a fourth being wheelchair dependent after
15 years.
The disease seems to follow a pattern of spatial progres-
sion from the early involvement of sensory neurons, to the
later appearance of vestibular and cerebellar dysfunction.
This is supported by: (i) the progression of symptoms, from
gait ataxia (median onset 55 years, range 30–80) and distal
sensory complaints (median onset 55 years, range 20–75),
to the later appearance of oscillopsia and visual disturb-
ances (median onset 62 years, range 44–80), dysarthria
(median onset 61, range 30–87) and dysphagia (median
onset 64 years, range 30–78); (ii) the higher frequency of
peripheral neuropathy as detected by nerve conduction stu-
dies (100%) compared to vestibular failure (80%) and
cerebellar dysfunction (60%) in the first available cross-
sectional examination; (iii) the higher frequency of periph-
eral neuropathy (100%) compared to vestibular failure
(93%, 69 of 74 tested) and cerebellar dysfunction (79%)
(Fig. 2B); and (iv) the presence (20%) of pure neuro-
pathic/neuronopathic forms as opposed to the absence of
isolated cerebellar or vestibular variants.
As sensory neuropathy is constant and pivotal to the
neurodegenerative process, additional considerations are
made here to characterize it further. In contrast to some
other hereditary sensory neuropathies, patients with bialle-
lic RFC1 expansions do not exhibit insensitivity to pain,
with painless injuries, ulceration and amputations. This
suggests that A and C fibre sensory neurons are selectively
spared. We postulate that large-diameter sensory neurons
innervating muscle spindles are also relatively spared, ex-
plaining the frequent occurrence of normal, if not brisk,
deep tendon reflexes in the context of a progressive loss
of A and Ab myelinated fibre sensory neurons, controlling
superficial sensation and proprioception. This observation
is consistent with previous reports of preserved H reflexes
in the upper and lower limbs of CANVAS patients (Burke
and Halmagyi, 2018; Infante et al., 2018).
Moreover, the observation of atrophy and T2-weighted
high signal intensity in the posterior columns on spine
MRI, together with the current findings on nerve conduc-
tion studies and previous ultrasound detection of small
diameter nerves (Pelosi et al., 2018), concordantly indicate
that a sensory neuronopathy, with combined degeneration
of central and peripheral projections of the T-shaped dorsal
root ganglion neurons, is part of the neurodegenerative
process in RFC1 biallelic expansions (Asbury, 1987;
Lauria et al., 2000; Camdessanche´ et al., 2009). The pri-
mary involvement of sensory neurons is further corrobo-
rated by the absence of significant regeneration on nerve
biopsies in the present study and confirms previous patho-
logical observations from two post-mortem CANVAS cases
of subtotal neuronal loss in the dorsal root ganglia, without
satellite cell proliferation (Szmulewicz et al., 2014)
Vestibular symptoms, including oscillopsia or more non-
specific visual disturbances while walking or during head
movements, were reported in a third of cases. Oscillopsia in
some cases was so severe that fixation and face recognition
became impossible during self-motion, typically walking or
travelling in cars. In contrast, rotational vertigo was not a
Figure 2 Involvement of peripheral nerve, cerebellum and
vestibular system in RFC1 biallelic expansion. (A) Symptoms
and signs. Clinical involvement of peripheral nerve (PN), vestibular
system (VS) and cerebellum (CBM) is defined as follows: (i) per-
ipheral nerve: sensory neuropathy: sensory symptoms (loss of
feeling, paraesthesia, dysesthesia, neuropathic pain) and/or abnormal
sensory examination including sensory ataxia; (ii) vestibular system:
bilateral vestibulopathy: presence of head movement-induced
oscillopsia and/or abnormal head impulse test; (iii) cerebellum:
cerebellar dysfunction: cerebellar dysarthria and/or dysphagia, ab-
normal eye movements (nystagmus, dysmetric saccades, broken
pursuits). (B) Symptoms, signs and investigations. In addition to the
clinical involvement as defined in A, investigational involvement of
the three main system affected in CANVAS was further identified by
(i) peripheral nerve: sensory neuropathy/neuronopathy on nerve
conduction studies; (ii) vestibular system: bilaterally abnormal video
head impulse test, bithermal caloric or motorized rotational tests;
and (iii) cerebellum: cerebellar atrophy on brain MRI. Abnormal in
55 of 59 (93%) with clinical information available. Abnormal in 69
of 74 (93%) with clinical and/or investigational information available.
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common complaint. However, this is not surprising as ro-
tational vertigo stems from an asymmetric dysfunction of
vestibular systems, and its absence in CANVAS syndrome
further supports the presence of a bilateral symmetrical de-
generative process. Subclinical vestibular involvement was
detected in an additional 30% cases if specifically looked
for, and it is likely to be underestimated in the present
series since bedside or video head impulse test were per-
formed only in half of the cases.
Two-thirds of patients had clinical and MRI evidence of
cerebellar involvement. In the context of severe sensory
ataxia, abnormal eye movements were often the first clue
to cerebellar involvement and were accompanied by dys-
arthria and dysphagia in the later stages of the disease
course.
An unexplained spasmodic dry cough was present in over
60% of patients and should be considered as part of this
complex neurodegenerative disease. Coughing, usually
occurring without a specific trigger, was reported up to
three decades before onset of difficulty walking and un-
steadiness, suggesting a particular susceptibility of neuronal
circuits controlling the cough reflex.
The disease-causing mechanisms of intronic RFC1 expan-
sions are still unknown. In our previous work we did not
detect reduced expression of RFC1 at either transcript or
protein level (Cortese et al., 2019). However a more subtle,
tissue- or time-specific loss-of-RFC1 function could not be
excluded (Cortese et al., 2019). A higher incidence of neo-
plasm might have been expected as the result of RFC1
dysfunction together with impaired DNA damage response.
Our results reported here and our previous work (Cortese
et al., 2019) do not support this hypothesis. This, together
with completely normal development, suggests that known
RFC1 biological functions are grossly preserved.
As the allele frequency of RFC1 AAGGG expansion
ranges from 1 to 5% of the healthy population (Cortese
et al., 2019; Rafehi et al., 2019), the estimated prevalence
at birth of biallelic carriers ranges from 1:10 000 to 1:400
individuals, suggesting that the disease is likely to be largely
underdiagnosed and, possibly, misdiagnosed. Indeed,
CANVAS was initially suspected in only 23% of the pa-
tients in the current series and one-third of cases were con-
sidered most likely to have an alternative diagnosis
including spino-cerebellar ataxia, mitochondrial disease,
multisystem atrophy-cerebellar subtype, or an acquired
autoimmune condition. This may partly be explained by
the relatively recent description of the clinical syndrome
(Szmulewicz et al., 2011). Patients frequently had costly
and/or invasive investigations including multiple genetic
tests and nerve and muscle biopsies. The availability of a
diagnostic test for CANVAS will ensure that patients re-
ceive a timely diagnosis.
Figure 3 Nerve biopsy findings in RFC1 biallelic repeat expansions. Severe loss of large and small myelinated fibres with no evidence of
ongoing axonal degeneration, no signs of regeneration and no features of demyelination is seen in all CANVAS patients with sensory neuropathy
due to RFC1 biallelic expansion. (A, A1, B and B1) Resin-embedded, semi-thin sections stained with methylene blue azure-basic fuchsin are
shown from two different patients. Occasional large remaining fibres in both cases are highlighted with a red arrow in A1 and B1. The
unmyelinated fibres in the peripheral nerves from CANVAS patients are comparably much better preserved. (C) Axons in formalin-fixed paraffin-
embedded tissue are shown on immunostaining with SMI31 antibody. (C1) A large residual axon is highlighted with red arrow and one of multiple
clusters of small unmyelinated fibres is shown with a blue arrow. Scale bars = 100 mm in A–C; 40 mm in A1–C1.
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Testing for the RFC1 repeat expansion should be con-
sidered in all cases with the full CANVAS phenotype as
well as in cases with sensory neuropathy, particularly, but
not only, if cerebellar, vestibular involvement and/or unex-
plained chronic cough coexist. The study highlights the im-
portance of a thorough clinical examination including
bedside head impulse testing in any patients with ataxia
regardless of whether the ataxia is considered to be due
to a neuropathy or cerebellar dysfunction.
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